Generic drug
Tapentadol price, strengths & recalls
Pharmacies pay $432.80 for 30 tablets of Tapentadol 100 mg tablet this week, and from $255.25 to $1,050.41 across its 6 priced strengths and forms. 4 manufacturers make it. Its official label last changed on March 4, 2026.
Generic- Fair cash price
- $508.22
- Strengths
- 6
- Makers
- 4
- Updated
- Nov 11
Tapentadol price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 50 mg (12 hr) extended-release tablet | $12.15 | $364.55 / 30 tablets | ||
| 100 mg (12 hr) extended-release tablet | $21.34 | $640.09 / 30 tablets | ||
| 200 mg (12 hr) extended-release tablet | $35.01 | $1,050.41 / 30 tablets | ||
| 20 mg/mL oral solution | Not priced this week | |||
| 50 mg tablet | $8.51 | $255.25 / 30 tablets | ||
| 75 mg tablet | $10.16 | $304.72 / 30 tablets | ||
| 100 mg tablet | $14.43 | $432.80 / 30 tablets | ||
The lowest cost per tablet is 50 mg tablet at $8.51. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Supply status: shortages & recalls
What people paid for Tapentadol
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use Tapentadol extended-release tablets safely and effectively. See full prescribing information for tapentadol extended-release tablet Tapentadol extended-release tablet for oral use C-II Initial U.S. Approval: 2008
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF TAPENTADOL EXTENDED-RELEASE TABLETS
Addiction, Abuse, and Misuse
Because the use of tapentadol extended-release tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death assess, each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1)].
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of tapentadol extended-release tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of tapentadol extended-release tablets are essential. Instruct patients to swallow tapentadol extended-release tablets whole; crushing, chewing, or dissolving tapentadol extended-release tablets can cause rapid release and absorption of a potentially fatal dose of tapentadol [see Warnings and Precautions (5.2)].
Accidental Ingestion
Accidental ingestion of even one dose of tapentadol extended-release tablets, especially by children, can result in a fatal overdose of tapentadol [see Warnings and Precautions (5.2)].
Interaction with Alcohol
Instruct patients not to consume alcoholic beverages or use prescription or nonprescription products that contain alcohol while taking tapentadol extended-release tablets. The co-ingestion of alcohol with tapentadol extended-release tablets may result in increased plasma tapentadol levels and a potentially fatal overdose of tapentadol [see Warnings and Precautions (5.2, 5.3)].
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of tapentadol extended-release tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3), Drug Interactions (7)].
Neonatal Opioid Withdrawal Syndrome (NOWS)
If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.4)].
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.5)].
WARNING: SERIOUS LIFE-THREATENING RISKS FROM USE OF TAPENTADOL extended-release tablet
See full prescribing information for complete boxed warning.
Tapentadol extended-release tablets expose users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk before prescribing and reassess regularly for development of these behaviors or conditions. (5.1)
Serious, life-threatening, or fatal respiratory depression may occur, especially upon initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of tapentadol extended-release tablets are essential. Instruct patients to swallow tapentadol extended-release tablets whole to avoid exposure to a potentially fatal dose of tapentadol. (2.1, 5.2)
Accidental ingestion of tapentadol extended-release tablets, especially in children, can result in fatal overdose of tapentadol. (5.2)
Instruct patients not to consume alcohol or any products containing alcohol while taking tapentadol extended-release tablets because co-ingestion can result in fatal plasma tapentadol levels. (5.3)
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.3, 7)
If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (5.4)
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (5.5)
Recent major changes (as listed on the label)
Boxed Warning | 12/2023 |
Indications and Usage (1) | 12/2023 |
Dosage and Administration (2.1, 2.3, 2.4) | 12/2023 |
Warnings and Precautions (5.6) | 12/2023 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA200533 · Collegium Pharm Inc
- First approved
- August 25, 2011 (15 years ago)
- Latest approved change
- June 18, 2026
- Approved label
- PDF, Dec 23, 2025
- Generic makers
- 3 approved generic applications on the market
- Last patent listed
- March 22, 2029
Tapentadol questions
How much does tapentadol cost without insurance?
Pharmacies pay about $432.80 for 30 tablets of tapentadol 100 mg tablet ($14.43 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $508.22. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is tapentadol in shortage?
No shortage is reported for tapentadol right now. We check the national shortage list every day.
Has tapentadol been recalled?
No recalls are on record for tapentadol.
When did the tapentadol label last change?
The official label was last updated on March 4, 2026 (version 3). See what changed.
Talk about tapentadol
No comments yet. Questions, tips, what worked for you - start the conversation.